The National Institute for Health and Clinical Excellence (NICE) has published guidance on rituximab, recommending it as a first-line treatment for patients with chronic lymphocytic leukaemia, who are able to take fludarabine in combination with cyclophosphamide. The guidance states that rituximab is not recommended in combination with any other chemotherapy agents.
Further reading - An in-depth review of the UK pharmaceutical market, including some background information on NICE, is available from Espicom: The Pharmaceutical Market: United Kingdom (published June 2009)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment